Giant cell arteritis

Clinical and Experimental Ophthalmology

Volumn 34, Issue 2, 2006, Pages 159-173

  Carroll, Stuart C ^a   Gaskin, Brent J ^a   Danesh Meyer, Helen V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Giant cell arteritis; Neuro ophthalmic disease; Neuro ophthalmology; Temporal arteritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DAPSONE; ETANERCEPT; ETIDRONIC ACID; GAMMA INTERFERON; GLUCOCORTICOID; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR4 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VITAMIN D;

ANAPHYLAXIS; AORTA; AORTA DISEASE; ARTERY INTIMA PROLIFERATION; ASEPTIC NECROSIS; BLOOD VESSEL BIOPSY; BLOOD VESSEL WALL; BRAIN VASCULITIS; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; EXTERNAL CAROTID ARTERY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC ANALYSIS; GIANT CELL ARTERITIS; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; INNATE IMMUNITY; INTERNAL CAROTID ARTERY; LABORATORY TEST; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RHEUMATIC POLYMYALGIA; SEPSIS; SIDE EFFECT; SUDDEN DEATH; SYMPTOMATOLOGY; THROMBOCYTE COUNT; ULTRASOUND; VASCULITIS; VERTEBRA FRACTURE; VISUAL DISORDER; VISUAL IMPAIRMENT;

HUMANS; OPTIC NERVE DISEASES; RETINAL DISEASES; TEMPORAL ARTERITIS; VISION DISORDERS;

EID: 33644791717     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01186.x     Document Type: Review

References (179)

1. Hayreh SS. Ophthalmic features of giant cell arteritis. Baillieres Clin Rheumatol 1991; 5: 431-59.
2. Danesh-Meyer H, Savino PJ, Gamble GD. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112: 1098-103.
3. Horton BT, Magath BT, Brown GE. Arteritis of temporal vessels: Report of 7 cases. Proc Staff Meet Mayo Clin 1937; 12: 548-53.
4. Jennings GH. Arteritis of the temporal vessels. Lancet 1938; 1: 424.
5. Gabriel SE, O'Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93-6.
6. Nordborg E, Nordborg C, Malmvall B, Andersson R, Bengtsson B. Giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 1013-26.
7. Machado EB, Michet CJ, Ballard DJ et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 1988; 31: 745-9.
8. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica, Incidences of difference clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.
9. Fauchald P, Rygvold O, Öystese B. Temporal arteritis and polymyalgia rheumatica. Ann Intern Med 1972; 77: 845-52.
10. Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med 1990; 227: 233-6.
11. Baldursson O, Steinsson K, Björnsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiological and histopathologic analysis. Arthritis Rheum 1994; 37: 1007-12.
12. Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: A prospective study 1987-94. J Rheumatol 1997; 24: 1739-43.
13. Kemp A. Monozygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmol (Copenh) 1977; 55: 183-90.
14. Wernick C, Duvey M, Bonafede P. Familial giant cell arteritis: Report of an HLA-typed sibling pair and review of the literature. Clin Exp Rheumatol 1994; 12: 63-6.
15. Barrier J, Bignon JD, Soullou JP, Grolleau J. Increased prevalence of HLA-DR4 in giant-cell arteritis. N Engl J Med 1981; 305: 104-5.
16. Calamia KT, Moore SB, Elveback LR, Hunder GG. HLA-DR locus antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1981; 8: 993-6.
17. Weyand CM, Hicok KC, Hunder G, Gm Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen-binding site of the HLA-DR molecule. J Clin Invest 1992; 90: 2355-61.
18. Rauzy O, Fort M, Nourhasemi F et al. Relation between HLA-DRB1 alleles corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998; 57: 380-2.
19. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998; 25: 2140-5.
20. Weyand CM, Hunder NNH, Hicock KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Arthritis Rheum 1994; 37: 514-20.
21. Mattey DL, Hajeer AH, Dababneh A et al. Association of giant cell arteritis and polymalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000; 43: 1749-55.
22. Boiardi L, Salvarani C, Timms JM, Silvestri T, Macchioni PL, Di Giovine FS. Interleukin-1 cluster and tumor necrosis factor-α gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18: 675-81.
23. Salvarani C, Casali B, Boiardi L et al. Intracellular adhesion molecule 1 polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2002; 29: 502-4.
24. Gonzalez-Gay MA. Genetic epidemiology in giant cell arteritis and polymyalgia rheumatica. Arthritis Res 2001; 3: 154-7.
25. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999; 17: 276-8.
26. Wilkinson IMS, Russell RWR. Arteries of the head and neck in giant cell arteritis. Arch Neurol 1972; 27: 378-91.
27. Nordborg E, Nordborg C. The inflammatory reaction in giant cell arteritis: An immunohistochemical investigation. Clin Exp Rheumatol 1998; 16: 165-8.
28. Weyand CM, Bartley GB. Giant cell arteritis: New concepts in pathogenesis and implications for management. Am J Ophthalmol 1997; 123: 392-5.
29. Poller DN, van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol 2000; 53: 137-9.
30. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21: 883-909.
31. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis. Arthritis Rheum 1999; 42: 1255-8.
32. Rimeti G, Blasi F, Cosentini R et al. Temporal Arteritis associated with Chlamydia pneumoniae DNA detected in an arterial speciman. J Rheumatol 2001; 28: 1738-9.
33. Nordborg C, Nordborg E, Petursdottir V et al. Search for Varicella zoster virus in giant cell arteritis. Ann Neurol 1998; 44: 413-14.
34. Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology 2002; 41: 445-9.
35. Rodriguez-Pla A, Bosch-Gil JA, Echevarria-Mayo JE et al. No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis. J Clin Virol 2004; 31: 11-15.
36. Regan MJ, Wood BJ, Hsieh YH et al. Temporal arteritis and Chlamydia pneumoniae: Failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002; 4: 1056-60.
37. Wells KK, Folberg R, Goeken JA, Kemp JD. Temporal artery biopsies. Correlation of light microscopy and immunofluoresence microscopy. Ophthalmology 1989; 96: 1058-64.
38. Weyand CM, Goronzy JJ. Medium and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9.
39. Ma-Krupa W, Kwan M, Goronzy JJ, Weyand CM. Toll-like receptors in giant cell arteritis. Clin Immunol 2005; 115: 38-46.
40. Wagner AD, Wittkop U, Prahst A et al. Dendritic cells colocalize with activated CD4+ T cells in giant cell arteritis. Clin Exp Rheumatol 2003; 21: 185-92.
41. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol 2000; 75: S9-15.
42. Weyand CM, Schonberger J, Oppitz U, Hunder NN, Hicik KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994; 179: 951-60.
43. Wagner AD, Bjornsson J, Bartley GB, Goronzy JJ, Weyand CM. Inferferon-gamma-producing T cells in giant cell vasculitis represent a minority of issue infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996; 148: 1925-33.
44. Hernadez-Rodriguez J, Segarra M, Vilardell C et al. Tissue production of pro-inflammatory cytokines correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004; 43: 294-301.
45. Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996; 98: 1642-9.
46. Kaiser M, Bjornssoj J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis. Platelet derived growth factor, intimal hyperplasia and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623-33.
47. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischaemic complications in giant cell arteritis. Circ Res 1999; 84: 1050.
48. PaPanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
49. Salvarini C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002; 347: 261-71.
50. Evans JM, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2000; 26: 493-515.
51. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: A 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80.
52. Weyand CM, Tetzlaff N, Bjorsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997; 40: 19-26.
53. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-83.
54. Weyand CM, Hicik KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 484-91.
55. Gonzales-Gay MA. Giant cell arteritis and polymyalgia rheumatica: Two different but often overlapping conditions. Semin Arthritis Rheum 2004; 33: 289-93.
56. Cantini F, Niccoli L, Storri L et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004; 33: 294-301.
57. Chan CCK, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-4.
58. Hayreh SS, Podhajsky P, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-96.
59. McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis: A clinicopathologic study. Ophthalmology 1986; 93: 518-30.
60. Healey LA. The relation of giant cell arteritis to polymyalgia rheumatica. Baillieres Clin Rheumatol 1991; 5: 371-8.
61. Gonzalez-Gay MA, Blanco R, Sanchez-Andrade A, Vasquez-Caruncho M. Giant cell arteritis in Lugo, Spain: A more frequent disease with fewer classic features. J Rheumatol 1997; 24: 2166-70.
62. Shenberger KN, Meharg JG, Lane CD. Temporal arteritis presenting as ataxia and dementia. Postgrad Med 1981; 69: 246-9.
63. Paulley JW, Hughes JP. Giant cell arteritis or arthritis of the aged. BMJ 1960; 2: 1562-7.
64. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am 1993; 19: 941-53.
65. Keltner JL. Giant-cell arteritis: Signs and symptoms. Ophthalmology 1982; 89: 1101-10.
66. Huston KA, Hunder GG, Lie JT et al. Temporal arteritis: A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88: 162-7.
67. Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological clinical and prognostic study. Scott Med J 1979; 24: 111-17.
68. Whitfield AGW, Bateman M, Trevor Cooke W. Temporal arteritis. Br J Ophthalmol 1963; 47: 555-66.
69. Cornblath WT, Eggenberger ER. Progressive visual loss form giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997; 104: 854-8.
70. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509-20.
71. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis of vision. Ophthalmology 1994; 101: 1779-85.
72. Foroozan R, Deramo VA, Buono LM et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003; 110: 539-42.
73. Hayreh SS. Anterior ischaemic optic neuropathy. II. Fundus on ophthalmoscopy and fluoroscein angiography. Br J Ophthalmol 1974; 58: 964-80.
74. Henkind P, Charles NC, Pearson J. Histopathology of ischaemic optic neuropathy. Am J Ophthalmol 1970; 69: 78-90.
75. Hayreh SS. Occlusion of the porterior ciliary artery. III. Effects on the optic nerve head. Br J Ophthalmol 1972; 56: 754-64.
76. Eagling EM, Sanders MD, Miller SJ. Ischaemic papillopathy. Clinical and fluorescein angiographic review of forty cases. Br J Ophthalmol 1974; 58: 990-1008.
77. Hayreh SS, Baines JAB. Occlusion of the posterior ciliary artery. I. Effects on choroidal circulation. Br J Ophthalmol 1972; 56: 719-35.
78. Melberg NS, Grant GM, Dieckert P et al. Cotton-wool spots and the early diagnosis of giant cell arteritis. Ophthalmology 1995; 102: 1611-14.
79. Spolaore R, Gaudric A, Coscas G et al. Acute sectorial choroidal ischemia. Am J Ophthalmol 1984; 98: 707-16.
80. Danesh-Meyer H, Savino M, Spaeth GL, Gamble GD. Comparison of artertic and nonarteritic anterior ischemic optic neuropathies with the Heidelberg Retina Tomograph. Ophthalmology 2005; 112: 1105-11.
81. Danesh-Meyer HV, Savino PJ, Eagle RC, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108: 593-8.
82. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of the literature. Acta Ophthalmol Scand 2002; 80: 355-67.
83. Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108: 1586-94.
84. Heptinstall RH, Prter KA, Barkley H. Giant-cell (temporal) arteritis. J Pathol Bacteriol 1954; 67: 507-19.
85. Meadows SP. Temporal or giant cell arteritis. Proc R Soc Med 1966; 59: 329-33.
86. Meadows SP. Blindness due to occlusive disease ('visual strokes'). Trans Ophthalmol Soc UK 1965; 85: 251-8.
87. Miller Fisher C. Ocular palsy in temporal arteritis. Minn Med 1959; 42: 1258-68.
88. Hall JK, Volpe NJ, Galetta SL, Liu GT, Syed NA, Balcer LJ. The role of unilateral temporal artery biopsy. Ophthalmology 2003; 110: 543-8.
89. Smetana GW, Shmerling RH. Does this patient have temporal arteritis. JAMA 2002; 287: 92-101.
90. Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis. A decision-analytic approach. Ophthalmology 2005; 112: 744-56.
91. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
92. Ellis ME, Ralston S. ESR in the diagnosis and management of polymyalgiarheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168-70.
93. Kyle V, Causton TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989; 48: 667-71.
94. Kyle V, Hazelman BL. Treatment of polymyalgia rheumatic and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.
95. Jacobson DM, Slamovits TL. Erythrocyte sedimentation rate and its relationship to hematocrit in giant cell arteritis. Arch Ophthalmol 1987; 105: 965-7.
96. Eshaghian J, Goeken JA. C-reactive protein in giant cell (cranial, temporal) arteritis. Ophthalmology 1980; 87: 1160-6.
97. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate. Arthritis Rheum 2001; 45: 140-5.
98. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. BMJ 1983; 286: 266.
99. Deodhar SD. C-reactive protein: The best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 1989; 56: 126-30.
100. Gudmunsson M, Nordborg E, Bengtsson BA, Bjelle A. Plasma viscosity in giant cell arteritis as a predictor of disease activity. Ann Rheum Dis 1993; 52: 104-9.
101. Lincoff NS, Erlich PD, Brass LS. Thrombocytosis in temporal arteritis. Rising platelet counts: A red flag for giant cell arteritis. J Neuroopthalmol 2000; 20: 67-72.
102. Zeidler C, Kanz L, Hukuck KL et al. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood 1992; 80: 2740-5.
103. Price N, Clearkin LG. Thrombocytosis and giant cell arteritis. Lancet 1994; 343: 672.
104. Krishna R, Kosmorsky DO. Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol 1997; 124: 103.
105. Foroozan R, Danesh-Meyer HV, Savino PJ et al. Thrombocytosis in patients with biopsy proven giant cell arteritis. Ophthalmology 2002; 109: 1267-71.
106. Bergstrom AL, Bengtsson BA, Olsson LB, Malmvall BE, Kutti J. Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. Ann Rheum Dis 1979; 38: 244-7.
107. Weiss LM, Gonzalez E, Miller SB, Agudelo CA. Severe anemia as a presenting manifestation of giant cell arteritis. Arthritis Rheum 1995; 38: 434-6.
108. Bates JH, Tomsak RL, Spedick MJ et al. Serum fibrinogen concentration in the diagnosis and management of biopsyproven giant-cell arteritis. Ophthalmology 1989; 96 (Suppl.): 105.
109. Brittain GP, McIlwaine GG, Bell JA, Gibson JM. Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis? Br J Ophthalmol 1991; 75: 656-9.
110. von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten year survey of 57 patients. Acta Med Scand 1979; 205: 429-35.
111. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis. Interleukin-6 as a biological marker of disease activity. Arthritis Rheum 2000; 43: 1041-8.
112. Espinosa G, Tassies D, Font J et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 2001; 31: 12-20.
113. Liozon E, Rablot P, Paire D et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant cell (temporal) arteritis. A longitudinal study of 58 biopsy proven cases. Rheumatology 2000; 39: 1089-94.
114. Huston KA, Hunder GG. Giant cell (cranial) arteritis: A clinical review. Am Heart J 1980; 100: 99-105.
115. Currey J. Scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 1997; 36: 814-16.
116. Stuart R. Temporal artery biopsy in suspected temporal arteritis: A five-year survey. N Z Med J 1989; 102: 431-3.
117. Barrier J, Potel G, Renaut Hovasse H et al. The use of Doppler flow studies in the diagnosis of giant cell arteritis. Selection of temporal artery biopsy site is facilitated. JAMA 1982; 248: 2158-9.
118. Cohen DN, Smith TR. Skip areas in temporal arteritis: Myth versus fact. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 772-83.
119. Albert DM, Ruchman MC, Keltner JL. Skip areas in temporal arteritis. Arch Ophthalmol 1976; 94: 2072-7.
120. Klein RG, Campbell RJ, Hunder GG et al. Skip lesions in temporal arteritis. Mayo Clin Proc 1976; 51: 504-10.
121. Albert DM, Searl SS, Craft JL. Histological and ultrastructural characteristics of temporal arteritis. The value of the temporal artery biopsy. Ophthalmology 1982; 89: 1111-26.
122. Danesh-Meyer HV, Savino PJ, Bilyk JR, Eagle RC, Sergott RC. Shrinkage: fact or fiction? Arch Ophthalmol 2001; 119: 1217.
123. Achkar AA, Lie JT, Hunder GG et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987-92.
124. Ray-Chaudhuri N, Ah Kine D, Tijani S et al. Effect of prior treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002; 86: 530-2.
125. Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis 1984; 43: 416-17.
126. McDonnell PJ, Moore GW, Miller NR et al. Temporal arteritis. A clinicopathologic study. Ophthalmology 1986; 93: 518-30.
127. Errlinger RE, Hunder GG, Ward LE. Polymyalgia rehumatica and giant cell arteritis. Annu Rev Med 1978; 29: 15-22.
128. Danesh-Meyer HV, Savino PJ, Eagle RC, Kubis KC, Sergott RC. Low diagnostic yield with second biopsies in suspected giant cell arteritis. J Neuroophthalmol 2000; 20: 213-15.
129. Hall S, Hunder GG. Is temporal artery biopsy prudent? Mayo Clin Proc 1984; 59: 793-6.
130. Ponge T, Barrier JH, Grolleau JY, Ponge A, Vlasak AM, Cottin S. The efficacy of selective unilateral temporal artery biopsy versus bilateral biopsies for diagnosis of giant cell arteritis. J Rheumatol 1988; 15: 997-1000.
131. Siatkowski RM, Gass DM, Glaser JS, Smith JL, Schatz NJ, Schiffman J. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993; 115: 57-63.
132. Mack HG, O'Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophthalmol 1991; 11: 221.
133. Ghanchi FD, Williamson TH, Lim CS et al. Colour Doppler imaging in giant cell (temporal) arteritis: Serial examination and comparison with non-arteritic anterior ischaemic optic neuropathy. Eye 1996; 10: 459-64.
134. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-42.
135. Hunder GG, Weyand CM. Sonography in giant cell arteritis. N Engl J Med 1997; 337: 1385-6.
136. Karassa FB, Matsagas MI, Schmidt WA, Ioanndis JP. Meta-analysis: Test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142: 359-69.
137. Atalay MK, Bluemke DA. Magnetic resonance imaging of large vessel vasculitis. Curr Opin Rheumatol 2001; 13: 41-7.
138. Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-resolution MRI in giant cell arteritis: Imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005; 184: 283-7.
139. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005; 32: 674-81.
140. de Leeuw K, Bijl M, Jager PL. Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculidites. Clin Exp Rheumatol 2004; 22 (6 Suppl. 36): S21-6.
141. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005; 17: 9-15.
142. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: Duration and treatment outcomes. Arthritis Rheum 2003; 49: 703-8.
143. Goodman BW Jr. Temporal arteritis. Am J Med 1979; 67: 839-52.
144. Hunder GG, Sheps SG, Allen GL et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann Intern Med 1975; 82: 613-18.
145. Salvarani C, Cantini F, Niccoli L et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective follow-up study. Arthritis Rheum 2005; 53: 33-8.
146. Swannell AJ. Polymyalgia rheumatica and temporal arteritis: Diagnosis and management. BMJ 1997; 314: 1329-32.
147. Kyle V. Treatment of polymyalgia rheumatica and giant cell arteritis. Baillieres Clin Rheumatol 1991; 5: 485-91.
148. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J et al. A strong initial inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant cell arteritis. Arthritis Rheum 2002; 47: 29-35.
149. Hayball PJ, Cosh DG, Ahern MJ, Schultz DW, Roberts-Thomson PJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmokinetics and clinical response. Eur J Clin Pharmacol 1992; 42: 85-8.
150. McGhee CN, Dean S, Danesh-Meyer HV. Locally administered ocular corticosteroids: Benefits and risks. Drug Saf 2002; 25: 33-55.
151. Bracken MB, Shephard MJ, Collins WF et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 1990; 332: 1405-11.
152. Hall ED. High dose glucocorticoid treatment improves neurological recovery in head-injured mice. J Neurosurg 1985; 62: 882-7.
153. Anderson DK, Means ED, Waters TR, Green ES. Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J Neurosurg 1982; 56: 106-13.
154. Young W, Flamm ES. Effect of high dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg 1982; 57: 667-73.
155. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382-7.
156. Reid IR. Preventing glucocorticoid-induced osteoporosis. N Engl J Med 1997; 337: 420-1.
157. Nuenninghoff DM, Matteson EL. The role of disease modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 2003; 21 (Suppl. 32): S29-34.
158. Caporali R, Cimmino MA, Ferraccioli GF et al. Prednisone plus methotrexate for polymyalgia rheumatica. Ann Intern Med 2004; 141: 493-500.
159. Spiera RF, Mitnick HJ, Kupersmith M et al. A prospective, double blind, randomized, placebo controlled trial of Methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501.
160. Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 5: 1309-18.
161. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
162. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/ polymyalgia rheumatica: A double-blind study. Ann Rheum Dis 1986; 45: 136-8.
163. Tan AL, Holdsworth J, Pease C, Emery P, Mcgonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003; 62: 373-4.
164. Airo P, Antoniolo CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology 2002; 41: 347-9.
165. Hoffman GS, Cid MC, Weyand CM et al. Phase II study of the safety and efficacy of infliximab in Giant Cell Arteritis (GCA): 22 week interim analysis. Unpublished abstract for American College of Rheumatology Annual Scientific Meeting, November 2005.
166. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose asprin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-7.
167. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-66.
168. Nesher G, Sonnenblick M. Steroid-sparing medications in temporal arteritis - report of three cases and review of 174 reported patients. Clin Rheumatol 1994; 13: 289-92.
169. Doury P, Pattin S, Eulry F, Thabaut A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1983; 26: 689-90.
170. De Vita S, Tavoni A, Jeracitano G et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992; 232: 373-5.
171. Buono LM, Foroozan R, deVirgiliis M, Savino PJ. Heparin therapy in giant cell arteritis [Letter]. Br J Ophthalmol 2004; 88: 298-301.
172. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204-15.
173. Aiello PD, Trautmann JC, McPhee TJ et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100: 550-5.
174. Chan CCK, O'Day J. Oral and intravenous steroids in giant cell arteritis. Clin Experiment Ophthalmol 2003; 31: 179-82.
175. Hayreh SS. Steroid therapy for visual loss in patients with giant cell arteritis. Lancet 2000; 355: 1572-3.
176. Morris CR, Scheib JS. Fatal myocardial infarction resulting from coronary arteritis in a patient with polymyalgia rheumatic and biopsy-proven temporal arteritis. A case report and review of the literature. Arch Intern Med 1994; 154: 1158-60.
177. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis - a population based study. Ann Intern Med 1995; 122: 502-7.
178. Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Kelley WN, Harris ED, Ruddy S et al., eds. Textbook of Rheumatology, 4th edn. Philadelphia, PA: W.B. Saunders, 1993; 1103-12.
179. Cullen JF, Coleiro JA. Ophthalmic complications of giant cell arteritis. Surv Ophthalmol 1976; 20: 247-60.